New Developments in the Management of Borderline Resectable Pancreatic Cancers

  • Martin David Goodman Tufts Medical Center. Boston, MA, USA
  • Sarah McPartland Tufts Medical Center. Boston, MA, USA
  • Kathryn Huber Tufts Medical Center. Boston, MA, USA
  • Muhammad Wasif Saif Tufts Medical Center. Boston, MA, USA
Keywords: Neoadjuvant Therapy, Pancreatic Neoplasms, Radiosurgery

Abstract

There remains great variability in the treatment for patients with borderline resectable pancreatic head cancers. Whether surgery should be attempted or neoadjuvant therapy consisting of chemoradiation or chemotherapy alone is at some debate. Each neoadjuvant regimen does show efficacy but there is no clear consensus which would be most beneficial. We will discuss three abstracts (#4043, #4057, #e15082) that were presented in the 2013 ASCO Annual Meeting that will discuss neoadjuvant therapies and how they are related to getting an R0 resection.

Image: Main atrium of Tufts Medical Center on the day of its renaming (March 4, 2008). Boston, MA, USA.

 

Downloads

Download data is not yet available.

Author Biographies

Martin David Goodman, Tufts Medical Center. Boston, MA, USA

Assitant Professor of Surgery

Division of Surgical Oncology

Sarah McPartland, Tufts Medical Center. Boston, MA, USA
Chief Surgical Resident
Kathryn Huber, Tufts Medical Center. Boston, MA, USA
Assistant Professor of Radiation Oncology
Muhammad Wasif Saif, Tufts Medical Center. Boston, MA, USA
Associate Professor of Medical Oncology

References

Varadhachary GR, Tamm EP, Abbruzzese JL, Xiong HQ, Crane CH, Wang H, Lee JE, Pisters PW, Evans DB, Wolff RA. Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy. Ann Surg Oncol. 2006 Aug;13(8):1035-46. Epub 2006 Jul 24.

Stokes JB, Nolan NJ, Stelow EB, et al. Preoperative capecitabine and concurrent radiation for borderline resectable pancreatic cancer. Ann Surg Oncol 2011; 18:619.

Mukherjee S, Hurt CN, Bridgewater J, et al. Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomized, phase 2 trial. Lancet Oncol 2013; 14:317.

Ishii H, Furuse J, Boku N, et al. Phase II study of gemcitabine chemotherapy alone for locally advanced pancreatic carcinoma: JCOG0506. Jpn J Clin Oncol 2010; 40:573.

Sahora K, Kuehrer I, Eisenhut A, et al. NeoGemOx: Gemcitabine and oxaliplatin as neoadjuvant treatment for locally advanced, nonmetastasized pancreatic cancer. Surgery 2011; 149:311.

Conroy T, Gavoille C, Samalin E, et al. The role of the FOLFIRINOX regimen for advanced pancreatic cancer. Curr Oncol Rep 2013; 15:182.

Rose J, Rocha F, Lin B, Alseidi A, Biehl T, et al. Extended neoadjuvant chemotherapy (CT) in borderline resectable pancreas (BRPC) cancer. J Clin Oncol 31,2013 (suppl; abstr 4043)

Dholakia AS, Hacker-Prietz A, Wild, AT, Raman SP, et al. Is successful resection following neoadjuvant radiation therapy for borderline resectable pancreatic cancer dependent on improved tumor-vessel relationships? J Clin Oncol 31, 2013 (suppl; abstr 4057)

Tsai S, Mahmoud A, George B, Kelly TR et al. Association of decline in serum CA19-9 after neoadjuvant therapy with improved survival among borderline resectable pancreatic cancer patients. J Clin Oncol 31, 2013 (suppl; abstr e15082)

Main atrium of Tufts Medical Center on the day of its renaming (March 4, 2008). Boston, MA, USA
Published
2013-07-10
How to Cite
Goodman, M., McPartland, S., Huber, K., & Saif, M. (2013). New Developments in the Management of Borderline Resectable Pancreatic Cancers. JOP. Journal of the Pancreas, 14(4), 334-336. https://doi.org/10.6092/1590-8577/1681
Section
Highlights from the “2013 ASCO Annual Meeting”. Chicago, IL, USA. May 31 - June 4, 2013

Most read articles by the same author(s)

1 2 > >>